The study is being led by Dr. Chase Heaton, M.D., a leading oncologic head and neck surgeon at UCSF, and was developed in collaboration with Dr. Alain Algazi,
Shingrix is a non-live and recombinant subunit adjuvanted vaccine, which will be administered intramuscularly in two doses. Shingles is caused by the reactivation of the varicella zoster virus
SORILUX is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and older. The FDA approved SORILUX in 2010 based on
Based in Copenhagen, Nuevolution shares its advanced discovery platform and programmes with pharmaceutical and biotechnology companies to develop novel medical treatment options for the patients. Amgen’s offer represents
WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai based Hile Bio-Technology (stock code 603718.SH). The business model of WuXi Vaccines is
Under the deal, Merck’s subsidiary will purchase all outstanding shares of Peloton in exchange for an upfront payment of $1.05bn (£825m) in cash. The shareholders of Peloton will
Takeda has granted a license to Phathom for the development and exclusive commercialization rights to vonoprazan in the United States, Europe and Canada in exchange for upfront cash
Venclexta/Venclyxto is a first-in-class targeted medicine that will selectively bind and restrict the B-cell lymphoma-2 (BCL-2) protein, while Gazyva/Gazyvaro is an engineered monoclonal antibody that will attach to
This is the first collaboration leveraging the ZymeLink platform and represents Zymeworks’ third technology platform licensed to a collaborator. “We believe this first ZymeLink licensing deal provides further
The approval was based on data from the phase III Javelin Renal 101 study, in which the combination significantly improved median progression-free survival (PFS) compared against sunitinib by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.